Datavault AI has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. The agreement enables Scilex to build and operate a Biotech Exchange platform to tokenize, trade, and monetize biotech assets such as genomic data, diagnostics, and drug information. This strategic partnership represents a significant advancement in applying blockchain and artificial intelligence technologies to the life sciences industry.
The licensing arrangement includes substantial financial components, with a $10 million upfront payment structured in four installments and potential milestone payments reaching up to $2.55 billion. Datavault AI expects the technology to expand into a Pharmaceutical Exchange platform addressing an estimated $2 trillion market opportunity. This expansion would provide companies with innovative pathways to access non-dilutive funding, potentially transforming how biotech and pharmaceutical firms finance research and development activities.
The technology is supported by Datavault AI's broad patent portfolio and proven high-performance computing expertise. The company's platform leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Additional information about the company's technology can be found at https://www.datavaultsite.com. The Information Data Exchange enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects.
This licensing agreement represents a major step in bridging advanced technology with the biopharmaceutical industry, potentially creating new paradigms for asset valuation and monetization in healthcare. The integration of AI-driven blockchain solutions could revolutionize how biotech companies manage and capitalize on their intellectual property and research assets. The platform's ability to tokenize complex biotech assets positions it as a potential game-changer in an industry increasingly focused on data-driven innovation and alternative financing models.
